Treating neuropsychiatric disorders with PDE10A inhibitors

Phosphodiesterase 10A (PDE10A) is a recently identified cyclic nucleotide phosphodiesterase expressed primarily in dopaminoreceptive medium spiny neurons of the striatum. This article provides a brief overview of the characterization, localization and function of this enzyme, the currently available...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today. Therapeutic strategies Vol. 3; no. 4; pp. 527 - 532
Main Authors Siuciak, Judith A., Strick, Christine A.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2006
Online AccessGet full text

Cover

More Information
Summary:Phosphodiesterase 10A (PDE10A) is a recently identified cyclic nucleotide phosphodiesterase expressed primarily in dopaminoreceptive medium spiny neurons of the striatum. This article provides a brief overview of the characterization, localization and function of this enzyme, the currently available pharmacological and genetic tools, and discusses recent data suggesting potential uses of PDE10A inhibitors in CNS disorders. David Sibley – National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, USA C. Anthony Altar – Psychiatric Genomics, Gaithersburg, USA Theresa Branchek – Lundbeck Research, Paramus, USA
ISSN:1740-6773
1740-6773
DOI:10.1016/j.ddstr.2006.10.012